



J. B. Chemicals & Pharmaceuticals Limited

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, May 23, 2012:

Audited Financial Results for the year 2011-12

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its audited financial results for the financial year ended on March 31, 2012. The financial results for the quarter/year ended on March 31, 2012 are strictly not comparable with the results of the respective corresponding period in the previous year due to divestment of Russia-CIS OTC business during the year, which was significant part of the company's business. The highlights of these results are as under.

Financial Highlight for the year 2011-12:

(Rs. in crores)

Particulars	Standalone		Consolidated	
	2011-12	2010-11	2011-12	2010-11
Revenue from operations (Net)	686.42	806.69	801.87	890.79
Other Income	28.51	5.88	28.98	6.16
Total Revenue	714.93	812.57	830.85	896.95
Profit before exceptional item & tax	48.63	140.95	82.85	165.24
Exceptional item ; Net Income on Sale of Russia-CIS OTC Business	760.59	---	760.59	---
Profit after tax	642.70	118.19	677.91	139.32
EPS (Rs.)	75.95	14.00	80.11	16.50
Book Value (Rs.)	112.61	84.40	114.51	81.82

The sales in domestic formulations remain the growth driver for the business. In that focus product group registered growth of 18%. This business has good growth potential and is poised to take advantage of growing domestic formulations market. The strategy is to focus on potential therapeutic groups coupled with enhanced penetration in Tier II cities and rural market, new product launches and increase in productivity. The growth is dependent on prescription generation, which is a slow process. However, the company is quite hopeful to achieve market growth.

The Rest of the world exports achieved growth of 37% with US market showing encouraging growth of 95%. The other markets such as Australia, Europe, Africa, Middle East and Asia too have shown good traction. The strategy in this business is

to focus on contract manufacturing to build sustainable revenue stream with continued focus on niche branded generics. Encouraged by success in US, the company plans to file 8-10 ANDAs every year. The company has State-of-the-Art manufacturing infrastructure for preparation like tablets, injectables and lozenges and some of these facilities are approved by international health authorities such as US FDA, UK MHRA, TGA Australia, MCC South Africa and ANVISA Brazil. The company plans to leverage this strength by developing lucrative contract manufacturing business.

The company is building up marketing team in Russia-CIS for prescription products. This will help build prescription products demand, which will accrue in coming years.

Dividend:

The board of directors have recommended final dividend of Re 1 (50%) per equity share of FV 2. This together with dividend distribution tax will absorb Rs. 9.84 crores. During the year, the company also paid special interim dividend of Rs. 40 per equity share of FV 2. The outgo on account of special interim dividend including dividend distribution tax was Rs. 393.78 crores.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe, Australia and Brazil. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.